This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • HIV/AIDS  • Cardiovascular Disease/ Myocardial Infarction  • Adverse Effects  • Alert me on articles by topic

Joan Stephenson, PhD

JAMA. 2005;293:2081.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Boston—One emerging concern regarding long-term treatment with highly active antiretroviral therapy (HAART)—an era that begin in the mid-1990s when protease inhibitors first became available and were combined with other classes of anti-HIV drugs—has been elevation in blood lipids and the potential for increased risk of heart disease. New findings from a large observational study presented at the 12th Annual Retrovirus Conference by Wafaa El-Sadr, MD, MPH, of Columbia University’s Mailman School of Public Health in New York City, revealed that the risk of myocardial infarction (MI) increases with longer exposure to HAART.

HAART results in a doubling of risk after 1 to 2 years, a risk similar to that imposed by smoking, the researchers found.

The findings were derived from the Data Collection on Adverse Events of Anti-HIV Drugs (known as the D:A:D Study), begun in 1999, which as of February 2004 included more than 76 000 . . . [Full Text of this Article]